$HURA Intismeran and IFx-2.0 take very different approaches to generating a patient-specific antitumor immune response.
neoantigens and importantly doesn’t require 6 to 9 weeks for each patient’s treatment tIt is immediately available to patients and injected directly into the tumor designed to use the patient’s own tumor as the neoantigen source, initiating the immune
$HURA Merck and Moderna’s positive Phase 3 results for intismeran autogene plus KEYTRUDA are an encouraging development for patient-specific cancer immunotherapy.
Intismeran uses sequencing and predictive selection to identify specific neoantigens for an individualized mRNA therapy, while IFx-2.0 is injected directly into the tumor and designed to expose the immune system to the neoantigens present there without requiring a separately
$HURA The Canaccord presentation gave investors a clearer view of the clinical sequence taking shape across TuHURA’s pipeline.
For retail investors following the story, the key point is how these programs build around a common focus: addressing resistance to cancer immunotherapies.
